Effective long-term immunosuppression in rats by subcutaneously implanted sustained-release tacrolimus pellet: Effect on spinally grafted human neural precursor survival

Experimental Neurology

Volumn 248, Issue , 2013, Pages 85-99

  Sevc, Juraj ^a,b   Goldberg, Danielle ^a   van Gorp, Sebastiaan ^c   Leerink, Marjolein ^a   Juhas, Stefan ^d   Juhasova, Jana ^d   Marsala, Silvia ^a   Hruska Plochan, Marian ^a,d,e   Hefferan, Michael P ^g   Motlik, Jan ^d   Rypacek, Frantisek ^f   Machova, Ludka ^f   Kakinohana, Osamu ^a   Santucci, Camila ^a   Johe, Karl ^g   Lukacova, Nadezda ^h   Yamada, Kazuhiko ⁱ   Bui, Jack D ^j   Marsala, Martin ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b P J AFÁRIK UNIVERSITY   (Slovakia)

^c MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^d INSTITUTE OF ANIMAL PHYSIOLOGY AND GENETICS   (Czech Republic)

^e CHARLES UNIVERSITY   (Czech Republic)

^f INSTITUTE OF MACROMOLECULAR CHEMISTRY   (Czech Republic)

^g Neuralstem Inc   (United States)

^h INSTITUTE OF CHEMISTRY   (Slovakia)

ⁱ MASSACHUSETTS GENERAL HOSPITAL   (United States)

^j UNIVERSITY OF CALIFORNIA   (United States)

more..

Author keywords

Human neural precursors; Immunosuppression; Spinal grafting; Sprague Dawley rat; T lymphocyte; Tacrolimus pellet; Xenograft

Indexed keywords

CASTOR OIL; LIPOSOME; MICROSPHERE; SODIUM CHLORIDE; SUPEROXIDE DISMUTASE; TACROLIMUS;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIODEGRADABLE IMPLANT; CELL MATURATION; CELL SURVIVAL; DRUG BLOOD LEVEL; DRUG DOSAGE FORM COMPARISON; GRAFT SURVIVAL; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOCYTIC INFILTRATION; NEURAL STEM CELL; NONHUMAN; PRIORITY JOURNAL; RAT; SPINE INJURY; STEM CELL TRANSPLANTATION; SUSTAINED RELEASE FORMULATION; T LYMPHOCYTE; TOXICITY TESTING; XENOGRAFT;

HUMAN NEURAL PRECURSORS; IMMUNOSUPPRESSION; SPINAL GRAFTING; SPRAGUE-DAWLEY RAT; T-LYMPHOCYTE; TACROLIMUS PELLET; XENOGRAFT;

ANIMALS; DELAYED-ACTION PREPARATIONS; DRUG IMPLANTS; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; NEURAL STEM CELLS; NEURONS; RATS; RATS, SPRAGUE-DAWLEY; SPINAL CORD; SPINAL CORD INJURIES; TACROLIMUS;

EID: 84879544196     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2013.05.017     Document Type: Article

References (42)

1. Barker R.A., Ratcliffe E., McLaughlin M., Richards A., Dunnett S.B. A role for complement in the rejection of porcine ventral mesencephalic xenografts in a rat model of Parkinson's disease. J. Neurosci. 2000, 20:3415-3424.
2. Barraclough K.A., Isbel N.M., Johnson D.W., Campbell S.B., Staatz C.E. Once- versus twice-daily tacrolimus: are the formulations truly equivalent?. Drugs 2011, 71:1561-1577.
3. Brevig T., Holgersson J., Widner H. Xenotransplantation for CNS repair: immunological barriers and strategies to overcome them. Trends Neurosci. 2000, 23:337-344.
4. Deacon T., Schumacher J., Dinsmore J., Thomas C., Palmer P., Kott S., Edge A., Penney D., Kassissieh S., Dempsey P., Isacson O. Histological evidence of fetal pig neural cell survival after transplantation into a patient with Parkinson's disease. Nat. Med. 1997, 3:350-353.
5. Finn W.F. FK506 nephrotoxicity. Ren. Fail. 1999, 21:319-329.
6. Gijsen V.M., de Wildt S.N., Tibboel D., Koren G. Tacrolimus-induced nephrotoxicity and genetic variability: a systematic review. Clin. Pharmacol. Ther. 2010, 87:S21-S.
7. Gold B.G., Katoh K., Stormdickerson T. The immunosuppressant FK506 increases the rate of axonal regeneration in rat sciatic nerve. J. Neurosci. 1995, 15:7509-7516.
8. Hall E.D., Oostveen J.A., Gurney M.E. Relationship of microglial and astrocytic activation to disease onset and progression in a transgenic model of familial ALS. Glia 1998, 23:249-256.
9. Halloran P.F. Molecular mechanisms of new immunosuppressants. Clin. Transplant. 1996, 10:118-123.
10. Hefferan M.P., Johe K., Hazel T., Feldman E.L., Lunn J.S., Marsala M. Optimization of immunosuppressive therapy for spinal grafting of human spinal stem cells in a rat model of ALS. Cell Transplant. 2011, 20:1153-1161.
11. Hefferan M.P., Galik J., Kakinohana O., Sekerkova G., Santucci C., Marsala S., Navarro R., Hruska-Plochan M., Johe K., Feldman E., Cleveland D.W., Marsala M. Human neural stem cell replacement therapy for amyotrophic lateral sclerosis by spinal transplantation. PLoS One 2012, 7:e42614.
12. Jockenhovel F., Vogel E., Kreutzer M., Reinhardt W., Lederbogen S., Reinwein D. Pharmacokinetics and pharmacodynamics of subcutaneous testosterone implants in hypogonadal men. Clin. Endocrinol. (Oxf) 1996, 45:61-71.
13. Johe K.K., Hazel T.G., Muller T., Dugich-Djordjevic M.M., McKay R.D. Single factors direct the differentiation of stem cells from the fetal and adult central nervous system. Genes Dev. 1996, 10:3129-3140.
14. Kakinohana O., Cizkova D., Tomori Z., Hedlund E., Marsala S., Isacson O., Marsala M. Region-specific cell grafting into cervical and lumbar spinal cord in rat: a qualitative and quantitative stereological study. Exp. Neurol. 2004, 190:122-132.
15. Kakinohana O., Juhasova J., Juhas S., Motlik J., Platoshyn O., Galik J., Hefferan M., Yuan S.H., Vidal J.G., Carson C.T., van Gorp S., Goldberg D., Leerink M., Lazar P., Marsala S., Miyanohara A., Keshavarzi S., Ciacci J.D., Marsala M. Survival and differentiation of human embryonic stem cell-derived neural precursors grafted spinally in spinal ischemia-injured rats or in naive immunosuppressed minipigs: a qualitative and quantitative study. Cell transplantation 2012, 21:2603-2619.
16. Kino T., Hatanaka H., Hashimoto M., Nishiyama M., Goto T., Okuhara M., Kohsaka M., Aoki H., Imanaka H. FK-506, a novel immunosuppressant isolated from a streptomyces. 1. Fermentation, isolation and physicochemical and biological characteristics. J. Antibiot. 1987, 40:1249-1255.
17. Ko S., Nakajima Y., Kanehiro H., Yoshimura A., Nakano H. The pharmacokinetic benefits of newly developed liposome-incorporated FK506. Transplantation 1994, 58:1142-1144.
18. Lama R., Santos F., Algar F.J., Alvarez A., Baamonde C. Lung transplants with tacrolimus and mycophenolate mofetil: a review. Transplant. Proc. 2003, 35:1968-1973.
19. MacGregor M.S., Bradley J.A. Overview of immunosuppressive therapy in organ-transplantation. Br. J. Hosp. Med. 1995, 54:276-284.
20. McAlister V.C. Liposomal tacrolimus: drug migration within blood compartments. Transplant. Proc. 1998, 30:1000-1001.
21. McKeon F. When worlds collide - immunosuppressant meet protein phosphatases. Cell 1991, 66:823-826.
22. Miyamoto Y., Uno T., Yamamoto H., Li X.K., Sakamoto K., Hashimoto H., Takenaka H., Kawashima Y., Kawarasaki H. Pharmacokinetic and immunosuppressive effects of tacrolimus-loaded biodegradable microspheres. Liver Transpl. 2004, 10:392-396.
23. Packard M.J. Use of slow-release pellets to administer calcitriol to avian embryos - effects on plasma calcium, magnesium and phosphorus. Gen. Comp. Endocrinol. 1992, 85:8-16.
24. Pirsch J.D., Miller J., Deierhoi M.H., Vincenti F., Filo R.S. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. Transplantation 1997, 63:977-983.
25. Przepiorka D., Devine S.M., Fay J.W., Uberti J.P., Wingard J.R. Practical considerations in the use of tacrolimus for allogeneic marrow transplantation. Bone Marrow Transplant. 1999, 24:1053-1056.
26. Reis A., Reinhard T., Sundmacher R., Braunstein C., Godehardt E. Effect of mycophenolate mofetil, cyclosporin A, and both in combination in a murine corneal graft rejection model. Br. J. Ophthalmol. 1998, 82:700-703.
27. Saxena K., Patro N., Patro I. FK506 protects neurons following peripheral nerve injury via immunosuppression. Cell. Mol. Neurobiol. 2007, 27:1049-1057.
28. Siekierka J.J., Hung S.H.Y., Poe M., Lin C.S., Sigal N.H. A cytosolic binding-protein for immunosuppressant FK506 has peptidyl-prolyl isomerase activity but is distinct from cyclophilin. Nature 1989, 341:755-757.
29. Srinivasan V., Pendergrass J.A., Kumar K.S., Landauer M.R., Seed T.M. Radioprotection, pharmacokinetic and behavioural studies in mouse implanted with biodegradable drug (amifostine) pellets. Int. J. Radiat. Biol. 2002, 78:535-543.
30. Staatz C.E., Tett S.E. Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation. Clin. Pharmacokinet. 2004, 43:623-653.
31. Studd J., Magos A. Hormone pellet implantation for menopause and premenstrual-syndome. Obstet. Gynecol. Clin. North Am. 1987, 14:229-249.
32. Su V.C.H., Greanya E.D., Ensom M.H.H. Impact of mycophenolate mofetil dose reduction on allograft outcomes in kidney transplant recipients on tacrolimus-based regimens: a systematic review. Ann. Pharmacother. 2011, 45:248-257.
33. Teh L.K., Dom S.H.M., Zakaria Z.A., Salleh M.Z. A systematic review of the adverse effects of tacrolimus in organ transplant patients. Afr. J. Pharm. Pharmacol. 2011, 5:764-771.
34. Thomson A.W., Bonham C.A., Zeevi A. Mode of action of tacrolimus (FK506) - molecular and cellular mechanisms. Ther. Drug Monit. 1995, 17:584-591.
35. Tze W.J., Tai J., Cheung S.S.C., Ricordi C., Starzl T.E. FK 506 - an effective immunosuppressant for islet xenotransplantation. Transplant. Proc. 1992, 24:2849-2850.
36. Usvald D., Vodicka P., Hlucilova J., Prochazka R., Motlik J., Kuchorova K., Johe K., Marsala S., Scadeng M., Kakinohana O., Navarro R., Santa M., Hefferan M.P., Yaksh T.L., Marsala M. Analysis of dosing regimen and reproducibility of intraspinal grafting of human spinal stem cells in immunosuppressed minipigs. Cell Transplant. 2010, 19:1103-1122.
37. Vicari-Christensen M., Repper S., Basile S., Young D. Tacrolimus: review of pharmacokinetics, pharmacodynamics, and pharmacogenetics to facilitate practitioners' understanding and offer strategies for educating patients and promoting adherence. Prog. Transplant. 2009, 19:277-284.
38. Wang Q.X., Uno T., Miyamoto Y., Hara Y., Kitazawa Y., Lu F.Z., Funeshima N., Fujino M., Yamamoto H., Takenaka H., Kawashima Y., Li X.K. Biodegradable microsphere-loaded tacrolimus enhanced the effect on mice islet allograft and reduced the adverse effect on insulin secretion. Am. J. Transplant. 2004, 4:721-727.
39. Wente M.N., Sauer P., Mehrabi A., Weitz J., Buchler M.W., Schmidt J., Schemmer P. Review of the clinical experience with a modified release form of tacrolimus [FK506E (MR4)] in transplantation. Clin. Transplant. 2006, 20:80-84.
40. Xu G.D., Wang L.Y., Chen W., Xue F., Bai X.L., Liang L., Shen X.N., Zhang M.L., Xia D.J., Liang T.B. Rapamycin and tacrolimus differentially modulate acute graft-versus-host disease in rats after liver transplantation. Liver Transpl. 2010, 16:357-363.
41. Yamauchi A., Oishi R., Kataoka Y. Tacrolimus-induced neurotoxicity and nephrotoxicity is ameliorated by administration in the dark phase in rats. Cell. Mol. Neurobiol. 2004, 24:695-704.
42. Yuan S.H., Martin J., Elia J., Flippin J., Paramban R.I., Hefferan M.P., Vidal J.G., Mu Y., Killian R.L., Israel M.A., Emre N., Marsala S., Marsala M., Gage F.H., Goldstein L.S., Carson C.T. Cell-surface marker signatures for the isolation of neural stem cells, glia and neurons derived from human pluripotent stem cells. PLoS One 2011, 6:e17540.